Tokyo, Japan April 17, 2006 - Astellas Pharma Inc. (President and CEO: Toichi Takenaka, "Astellas") today announced that the total consideration for the sale of all outstanding shares of Zepharma Inc.(President: Masaji Oe, "Zepharma"), which was its fully owned OTC subsidiary, has been fixed with 35.5 billion yen.

The transaction of all outstanding shares of Zepharma to Daiichi Sankyo Co., Ltd. (President and CEO: Takashi Shoda) was closed on April 13, 2006 as scheduled and Astellas received 23.5 billion yen in cash at the closing date. Additional cash payment as adjustments of cash etc. owned by Zepharma as of the closing date were fixed today.

With the fix of the total consideration, extraordinary profit which Astellas will record for the fiscal year ending March 2007 due to the sale of Zepharma shares will be 21.2 billion yen on a consolidated basis.

Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)